{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:55:52Z","timestamp":1791219352211,"version":"4.1.0"},"reference-count":282,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Immunol"],"DOI":"10.1038\/s41577-026-01330-1","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:38:32Z","timestamp":1784212712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interleukin-18 armours antitumour immune effectors"],"prefix":"10.1038","author":[{"given":"Akshat","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina G.","family":"Bishara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-5554","authenticated-orcid":false,"given":"Scott H.","family":"Olejniczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce E.","family":"Ohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3364-5388","authenticated-orcid":false,"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6074-9847","authenticated-orcid":false,"given":"Ajay","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"1330_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1128\/iai.57.2.590-595.1989","volume":"57","author":"K Nakamura","year":"1989","unstructured":"Nakamura, K., Okamura, H., Wada, M., Nagata, K. & Tamura, T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 57, 590\u2013595 (1989).","journal-title":"Infect. Immun."},{"key":"1330_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/378088a0","volume":"378","author":"H Okamura","year":"1995","unstructured":"Okamura, H. et al. Cloning of a new cytokine that induces IFN-\u03b3 production by T cells. Nature 378, 88\u201391 (1995).","journal-title":"Nature"},{"key":"1330_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/379591a0","volume":"379","author":"JF Bazan","year":"1996","unstructured":"Bazan, J. F., Timans, J. C. & Kastelein, R. A. A newly defined interleukin-1? Nature 379, 591\u2013591 (1996).","journal-title":"Nature"},{"key":"1330_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1038\/s41467-018-03362-1","volume":"9","author":"J Rivers-Auty","year":"2018","unstructured":"Rivers-Auty, J., Daniels, M. J. D., Colliver, I., Robertson, D. L. & Brough, D. Redefining the ancestral origins of the interleukin-1 superfamily. Nat. Commun. 9, 1156 (2018).","journal-title":"Nat. Commun."},{"key":"1330_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10555-006-9013-3","volume":"25","author":"F Vidal-Vanaclocha","year":"2006","unstructured":"Vidal-Vanaclocha, F. et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 25, 417\u2013434 (2006).","journal-title":"Cancer Metastasis Rev."},{"key":"1330_CR6","doi-asserted-by":"publisher","first-page":"F11","DOI":"10.1084\/jem.194.3.F11","volume":"194","author":"SL Swain","year":"2001","unstructured":"Swain, S. L. Interleukin 18: tipping the balance towards a T helper cell 1 response. J. Exp. Med. 194, F11\u2013F14 (2001).","journal-title":"J. Exp. Med."},{"key":"1330_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00262-013-1403-0","volume":"62","author":"S Srivastava","year":"2013","unstructured":"Srivastava, S. et al. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol. Immunother. 62, 1073\u20131082 (2013).","journal-title":"Cancer Immunol. Immunother."},{"key":"1330_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cellimm.2004.02.002","volume":"227","author":"J Li","year":"2004","unstructured":"Li, J. et al. Induction of dendritic cell maturation by IL-18. Cell Immunol. 227, 103\u2013108 (2004).","journal-title":"Cell Immunol."},{"key":"1330_CR9","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.4049\/jimmunol.166.5.3075","volume":"166","author":"H Schindler","year":"2001","unstructured":"Schindler, H., Lutz, M. B., R\u00f6llinghoff, M. & Bogdan, C. The production of IFN-gamma by IL-12\/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J. Immunol. 166, 3075\u20133082 (2001).","journal-title":"J. Immunol."},{"key":"1330_CR10","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1158\/1078-0432.CCR-06-0121","volume":"12","author":"MJ Robertson","year":"2006","unstructured":"Robertson, M. J. et al. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin. Cancer Res. 12, 4265\u20134273 (2006). The initial study of recombinant human IL-18 in patients with advanced cancer, demonstrating safety.","journal-title":"Clin. Cancer Res."},{"key":"1330_CR11","doi-asserted-by":"publisher","first-page":"1533808","DOI":"10.3389\/fonc.2025.1533808","volume":"15","author":"Y Ohno","year":"2025","unstructured":"Ohno, Y., Okamura, H., Yagita, H. & Tanaka, T. IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade. Front. Oncol. 15, 1533808 (2025).","journal-title":"Front. Oncol."},{"key":"1330_CR12","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/1078-0432.CCR-15-1655","volume":"22","author":"Z Ma","year":"2016","unstructured":"Ma, Z. et al. Augmentation of immune checkpoint cancer immunotherapy with IL18. Clin. Cancer Res. 22, 2969\u20132980 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1330_CR13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/blood.2025029532","volume":"146","author":"MB Geyer","year":"2025","unstructured":"Geyer, M. B. et al. CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. Blood 146, 3163\u20133174 (2025).","journal-title":"Blood"},{"key":"1330_CR14","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2024-194391","volume":"144","author":"S Shahid","year":"2024","unstructured":"Shahid, S. et al. Developing an optimal fully-human CD371-targeting IL-18 secreting CAR T cell for the treatment of acute myeloid leukemia. Blood 144, 3406\u20133406 (2024).","journal-title":"Blood"},{"key":"1330_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00262-004-0654-1","volume":"54","author":"YF He","year":"2005","unstructured":"He, Y. F. et al. Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol. Immunother. 54, 891\u2013897 (2005).","journal-title":"Cancer Immunol. Immunother."},{"key":"1330_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","volume":"8","author":"D Jorgovanovic","year":"2020","unstructured":"Jorgovanovic, D., Song, M., Wang, L. & Zhang, Y. Roles of IFN-\u03b3 in tumor progression and regression: a review. Biomark. Res. 8, 49 (2020).","journal-title":"Biomark. Res."},{"key":"1330_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1084\/jem.20160880","volume":"214","author":"AJ Lee","year":"2017","unstructured":"Lee, A. J. et al. Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection. J. Exp. Med. 214, 1153\u20131167 (2017).","journal-title":"J. Exp. Med."},{"key":"1330_CR18","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1002\/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q","volume":"28","author":"S Stoll","year":"1998","unstructured":"Stoll, S. et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur. J. Immunol. 28, 3231\u20133239 (1998).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR19","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.4049\/jimmunol.162.11.6829","volume":"162","author":"TT Pizarro","year":"1999","unstructured":"Pizarro, T. T. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn\u2019s disease: expression and localization in intestinal mucosal cells. J. Immunol. 162, 6829\u20136835 (1999).","journal-title":"J. Immunol."},{"key":"1330_CR20","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41419-023-06221-0","volume":"14","author":"K Kadono","year":"2023","unstructured":"Kadono, K. et al. SIRT1 regulates hepatocyte programmed cell death via GSDME - IL18 axis in human and mouse liver transplantation. Cell Death Dis. 14, 762 (2023).","journal-title":"Cell Death Dis."},{"key":"1330_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1046\/j.1365-2133.2000.03759.x","volume":"143","author":"JB Mee","year":"2000","unstructured":"Mee, J. B., Alam, Y. & Groves, R. W. Human keratinocytes constitutively produce but do not process interleukin-18. Br. J. Dermatol. 143, 330\u2013336 (2000).","journal-title":"Br. J. Dermatol."},{"key":"1330_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1172\/JCI1333","volume":"101","author":"NJ Horwood","year":"1998","unstructured":"Horwood, N. J. et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 101, 595\u2013603 (1998).","journal-title":"J. Clin. Invest."},{"key":"1330_CR23","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1172\/JCI7317","volume":"104","author":"JA Gracie","year":"1999","unstructured":"Gracie, J. A. et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104, 1393\u20131401 (1999).","journal-title":"J. Clin. Invest."},{"key":"1330_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.4049\/jimmunol.162.2.1096","volume":"162","author":"T Olee","year":"1999","unstructured":"Olee, T., Hashimoto, S., Quach, J. & Lotz, M. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J. Immunol. 162, 1096\u20131100 (1999).","journal-title":"J. Immunol."},{"key":"1330_CR25","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.4049\/jimmunol.148.11.3596","volume":"148","author":"T Yoshimoto","year":"1992","unstructured":"Yoshimoto, T. et al. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1\/tumor necrosis factor. J. Immunol. 148, 3596\u20133603 (1992).","journal-title":"J. Immunol."},{"key":"1330_CR26","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4049\/jimmunol.162.3.1662","volume":"162","author":"Y Hyodo","year":"1999","unstructured":"Hyodo, Y. et al. IL-18 up-regulates perforin-mediated NK activity without increasing perforin messenger RNA expression by binding to constitutively expressed IL-18 receptor. J. Immunol. 162, 1662\u20131668 (1999).","journal-title":"J. Immunol."},{"key":"1330_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41568-023-00562-w","volume":"23","author":"B Ruf","year":"2023","unstructured":"Ruf, B., Greten, T. F. & Korangy, F. Innate lymphoid cells and innate-like T cells in cancer \u2014 at the crossroads of innate and adaptive immunity. Nat. Rev. Cancer 23, 351\u2013371 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1330_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1165\/rcmb.2003-0306OC","volume":"31","author":"Y Kitasato","year":"2004","unstructured":"Kitasato, Y. et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 31, 619\u2013625 (2004).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"1330_CR29","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.4049\/jimmunol.2300065","volume":"210","author":"M Harel","year":"2023","unstructured":"Harel, M., Fauteux-Daniel, S., Rodriguez, E., Palmer, G. & Gabay, C. IL-18 binding protein-producing cells attenuate anemia in murine macrophage activation syndrome. J. Immunol. 210, 1790\u20131803 (2023).","journal-title":"J. Immunol."},{"key":"1330_CR30","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.4049\/jimmunol.167.5.2879","volume":"167","author":"BP Leung","year":"2001","unstructured":"Leung, B. P. et al. A role for IL-18 in neutrophil activation. J. Immunol. 167, 2879\u20132886 (2001).","journal-title":"J. Immunol."},{"key":"1330_CR31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.anai.2013.09.004","volume":"112","author":"H Oda","year":"2014","unstructured":"Oda, H. et al. Interleukin-18 expression, CD8+ T cells, and eosinophils in lungs of nonsmokers with fatal asthma. Ann. Allergy Asthma Immunol. 112, 23\u201328.e21 (2014).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"1330_CR32","doi-asserted-by":"publisher","first-page":"13962","DOI":"10.1073\/pnas.96.24.13962","volume":"96","author":"T Yoshimoto","year":"1999","unstructured":"Yoshimoto, T. et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl Acad. Sci. USA 96, 13962\u201313966 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4743176","volume":"2016","author":"J Wang","year":"2016","unstructured":"Wang, J. et al. Correlation of IL-18 with tryptase in atopic asthma and induction of mast cell accumulation by IL-18. Mediat. Inflamm. 2016, 4743176 (2016).","journal-title":"Mediat. Inflamm."},{"key":"1330_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s10753-016-0467-3","volume":"40","author":"MH Xu","year":"2017","unstructured":"Xu, M. H. et al. Association of interleukin-18 and asthma. Inflammation 40, 324\u2013327 (2017).","journal-title":"Inflammation"},{"key":"1330_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.molimm.2018.12.024","volume":"107","author":"J Deng","year":"2019","unstructured":"Deng, J., Yu, X. Q. & Wang, P. H. Inflammasome activation and Th17 responses. Mol. Immunol. 107, 142\u2013164 (2019).","journal-title":"Mol. Immunol."},{"key":"1330_CR36","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/intimm\/dxr001","volume":"23","author":"LA Zenewicz","year":"2011","unstructured":"Zenewicz, L. A. & Flavell, R. A. Recent advances in IL-22 biology. Int. Immunol. 23, 159\u2013163 (2011).","journal-title":"Int. Immunol."},{"key":"1330_CR37","doi-asserted-by":"publisher","first-page":"155932582093136","DOI":"10.1177\/1559325820931360","volume":"18","author":"Z Yao","year":"2020","unstructured":"Yao, Z. et al. Prognostic role of IL-18 in various human cancers and radiation injuries: a meta-analysis. Dose Response 18, 1559325820931360 (2020).","journal-title":"Dose Response"},{"key":"1330_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.bbrc.2015.02.108","volume":"459","author":"Y Yang","year":"2015","unstructured":"Yang, Y. et al. Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway. Biochem. Biophys. Res. Commun. 459, 379\u2013386 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1330_CR39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello, C. A. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol. Rev. 281, 8\u201327 (2018).","journal-title":"Immunol. Rev."},{"key":"1330_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6340","volume":"5","author":"N Tsutsumi","year":"2014","unstructured":"Tsutsumi, N. et al. The structural basis for receptor recognition of human interleukin-18. Nat. Commun. 5, 5340 (2014).","journal-title":"Nat. Commun."},{"key":"1330_CR41","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.4049\/jimmunol.161.7.3400","volume":"161","author":"T Yoshimoto","year":"1998","unstructured":"Yoshimoto, T. et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J. Immunol. 161, 3400\u20133407 (1998).","journal-title":"J. Immunol."},{"key":"1330_CR42","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.4049\/jimmunol.165.4.1933","volume":"165","author":"T Sareneva","year":"2000","unstructured":"Sareneva, T., Julkunen, I. & Matikainen, S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol. 165, 1933\u20131938 (2000).","journal-title":"J. Immunol."},{"key":"1330_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1359-6101(00)00015-0","volume":"12","author":"K Nakanishi","year":"2001","unstructured":"Nakanishi, K., Yoshimoto, T., Tsutsui, H. & Okamura, H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev. 12, 53\u201372 (2001).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1330_CR44","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.virol.2003.11.005","volume":"319","author":"W Xiong","year":"2004","unstructured":"Xiong, W. et al. Interferon-inducible MyD88 protein inhibits hepatitis B virus replication. Virology 319, 306\u2013314 (2004).","journal-title":"Virology"},{"key":"1330_CR45","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1002\/1521-4141(200107)31:7<2236::AID-IMMU2236>3.0.CO;2-G","volume":"31","author":"S Matikainen","year":"2001","unstructured":"Matikainen, S. et al. IFN-\u03b1 and IL-18 synergistically enhance IFN-\u03b3 production in human NK cells: differential regulation of Stat4 activation and IFN-\u03b3 gene expression by IFN-\u03b1 and IL-12. Eur. J. Immunol. 31, 2236\u20132245 (2001).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1074-7613(00)80596-8","volume":"9","author":"O Adachi","year":"1998","unstructured":"Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9, 143\u2013150 (1998).","journal-title":"Immunity"},{"key":"1330_CR47","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1084\/jem.20100199","volume":"207","author":"R Salcedo","year":"2010","unstructured":"Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625\u20131636 (2010).","journal-title":"J. Exp. Med."},{"key":"1330_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.molimm.2021.07.001","volume":"137","author":"KJ Dixon","year":"2021","unstructured":"Dixon, K. J. et al. MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infection. Mol. Immunol. 137, 94\u2013104 (2021).","journal-title":"Mol. Immunol."},{"key":"1330_CR49","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136093","volume":"5","author":"B Prinzing","year":"2020","unstructured":"Prinzing, B. et al. MyD88\/CD40 signaling retains CAR T cells in a less differentiated state. JCI Insight 5, e136093 (2020).","journal-title":"JCI Insight"},{"key":"1330_CR50","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/bloodadvances.2020001510","volume":"4","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Inducible MyD88\/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells. Blood Adv. 4, 1950\u20131964 (2020).","journal-title":"Blood Adv."},{"key":"1330_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jimmun\/vkae037","volume":"214","author":"AL Bayer","year":"2025","unstructured":"Bayer, A. L., Magri, Z., Muendlein, H., Poltorak, A. & Alcaide, P. MyD88 determines T cell fate through BCAP-PI3K signaling. J. Immunol. 214, 433\u2013445 (2025).","journal-title":"J. Immunol."},{"key":"1330_CR52","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1161\/CIRCRESAHA.123.323030","volume":"133","author":"AL Bayer","year":"2023","unstructured":"Bayer, A. L. et al. T-cell MyD88 Is a novel regulator of cardiac fibrosis through modulation of T-cell activation. Circ. Res. 133, 412\u2013429 (2023).","journal-title":"Circ. Res."},{"key":"1330_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s40425-019-0652-7","volume":"7","author":"YH Choi","year":"2019","unstructured":"Choi, Y. H. et al. IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells. J. Immunother. Cancer 7, 168 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR54","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.4049\/jimmunol.170.11.5464","volume":"170","author":"M Strengell","year":"2003","unstructured":"Strengell, M. et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol. 170, 5464\u20135469 (2003).","journal-title":"J. Immunol."},{"key":"1330_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adq8778","volume":"18","author":"L Fallone","year":"2025","unstructured":"Fallone, L. et al. Interleukins 15 and 18 synergistically prime the antitumor function of natural killer cells through noncanonical activation of mTORC1. Sci. Signal. 18, eadq8778 (2025).","journal-title":"Sci. Signal."},{"key":"1330_CR56","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.4049\/jimmunol.167.3.1306","volume":"167","author":"M Nakahira","year":"2001","unstructured":"Nakahira, M. et al. An absolute requirement for STAT4 and a role for IFN-gamma as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J. Immunol. 167, 1306\u20131312 (2001).","journal-title":"J. Immunol."},{"key":"1330_CR57","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.4049\/jimmunol.168.3.1146","volume":"168","author":"M Nakahira","year":"2002","unstructured":"Nakahira, M. et al. Synergy of IL-12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J. Immunol. 168, 1146\u20131153 (2002).","journal-title":"J. Immunol."},{"key":"1330_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bbmt.2014.01.006","volume":"20","author":"JW Leong","year":"2014","unstructured":"Leong, J. W. et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol. Blood Marrow Transplant. 20, 463\u2013473 (2014).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"1330_CR59","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1182\/blood-2012-04-419283","volume":"120","author":"R Romee","year":"2012","unstructured":"Romee, R. et al. Cytokine activation induces human memory-like NK cells. Blood 120, 4751\u20134760 (2012). This paper highlights pre-activation of IL-18-containing cytokine combinations on NK cell phenotype and function.","journal-title":"Blood"},{"key":"1330_CR60","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1084\/jem.194.8.1187","volume":"194","author":"JP Lodolce","year":"2001","unstructured":"Lodolce, J. P., Burkett, P. R., Boone, D. L., Chien, M. & Ma, A. T cell-independent interleukin 15Ralpha signals are required for bystander proliferation. J. Exp. Med. 194, 1187\u20131194 (2001).","journal-title":"J. Exp. Med."},{"key":"1330_CR61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1074-7613(02)00429-6","volume":"17","author":"S Dubois","year":"2002","unstructured":"Dubois, S., Mariner, J., Waldmann, T. A. & Tagaya, Y. IL-15R\u03b1\u00a0recycles and presents IL-15 in trans to neighboring cells. Immunity 17, 537\u2013547 (2002).","journal-title":"Immunity"},{"key":"1330_CR62","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fimmu.2016.00101","volume":"7","author":"CM Nielsen","year":"2016","unstructured":"Nielsen, C. M., Wolf, A. S., Goodier, M. R. & Riley, E. M. Synergy between common \u03b3 chain family cytokines and IL-18 potentiates innate and adaptive pathways of NK cell activation. Front. Immunol. 7, 101 (2016).","journal-title":"Front. Immunol."},{"key":"1330_CR63","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1002\/eji.201546018","volume":"45","author":"KA Stegmann","year":"2015","unstructured":"Stegmann, K. A., De Souza, J. B. & Riley, E. M. IL-18-induced expression of high-affinity IL-2R on murine NK cells is essential for NK-cell IFN-\u03b3 production during murine Plasmodium yoelii infection. Eur. J. Immunol. 45, 3431\u20133440 (2015).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR64","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/JLB.1HI1017-396RR","volume":"104","author":"Y El-Darawish","year":"2018","unstructured":"El-Darawish, Y. et al. Frontline science: IL-18 primes murine NK cells for proliferation by promoting protein synthesis, survival, and autophagy. J. Leukoc. Biol. 104, 253\u2013264 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"1330_CR65","doi-asserted-by":"publisher","first-page":"e14511","DOI":"10.1200\/JCO.2022.40.16_suppl.e14511","volume":"40","author":"TV Shamova","year":"2022","unstructured":"Shamova, T. V. et al. Interleukins of the IL-2 family have different activity against natural killer cells when used in combination with IL-18. J. Clin. Oncol. 40, e14511\u2013e14511 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1330_CR66","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bbrc.2020.12.012","volume":"534","author":"M Liu","year":"2021","unstructured":"Liu, M., Meng, Y., Zhang, L., Han, Z. & Feng, X. High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18. Biochem. Biophys. Res. Commun. 534, 149\u2013156 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1330_CR67","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/s41590-025-02270-z","volume":"26","author":"D Granadier","year":"2025","unstructured":"Granadier, D. et al. Damage-induced IL-18 stimulates thymic NK cells limiting endogenous tissue regeneration. Nat. Immunol. 26, 1699\u20131711 (2025).","journal-title":"Nat. Immunol."},{"key":"1330_CR68","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.3389\/fimmu.2018.02796","volume":"9","author":"JHW Pahl","year":"2018","unstructured":"Pahl, J. H. W., Cerwenka, A. & Ni, J. Memory-like NK cells: remembering a previous activation by cytokines and NK cell receptors. Front. Immunol. 9, 2796 (2018).","journal-title":"Front. Immunol."},{"key":"1330_CR69","doi-asserted-by":"publisher","first-page":"822","DOI":"10.4314\/ahs.v20i2.36","volume":"20","author":"W Widowati","year":"2020","unstructured":"Widowati, W. et al. Effect of interleukins (IL-2, IL-15, IL-18) on receptors activation and cytotoxic activity of natural killer cells in breast cancer cell. Afr. Health Sci. 20, 822\u2013832 (2020).","journal-title":"Afr. Health Sci."},{"key":"1330_CR70","first-page":"13","volume":"2","author":"Z Liu","year":"2002","unstructured":"Liu, Z. et al. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871. Cancer Immun. 2, 13 (2002).","journal-title":"Cancer Immun."},{"key":"1330_CR71","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood.V122.21.4501.4501","volume":"122","author":"R Romee","year":"2013","unstructured":"Romee, R. et al. Human cytokine-induced memory-like (CIML) NK cells exhibit potent anti-leukemia cytotoxicity and maintain memory-like functionality after adoptive transfer into immunodeficient NOD-SCID-Gc\u2212\/\u2212 (NSG) mice. Blood 122, 4501 (2013).","journal-title":"Blood"},{"key":"1330_CR72","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1182\/blood.V99.4.1289","volume":"99","author":"M Okamoto","year":"2002","unstructured":"Okamoto, M. et al. Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia. Blood 99, 1289\u20131298 (2002).","journal-title":"Blood"},{"key":"1330_CR73","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.4049\/jimmunol.162.9.5070","volume":"162","author":"T Hoshino","year":"1999","unstructured":"Hoshino, T., Wiltrout, R. H. & Young, H. A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 162, 5070\u20135077 (1999).","journal-title":"J. Immunol."},{"key":"1330_CR74","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1084\/jem.194.2.143","volume":"194","author":"RB Smeltz","year":"2001","unstructured":"Smeltz, R. B., Chen, J., Hu-Li, J. & Shevach, E. M. Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1\/Th2 differentiation. Critical downregulatory role of IL-4. J. Exp. Med. 194, 143\u2013153 (2001).","journal-title":"J. Exp. Med."},{"key":"1330_CR75","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.4049\/jimmunol.174.5.2796","volume":"174","author":"MC Rodriguez-Gal\u00e1n","year":"2005","unstructured":"Rodriguez-Gal\u00e1n, M. C., Bream, J. H., Farr, A. & Young, H. A. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1\/Th2 cytokine expression. J. Immunol. 174, 2796\u20132804 (2005).","journal-title":"J. Immunol."},{"key":"1330_CR76","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/intimm\/dxl058","volume":"18","author":"H Ito","year":"2006","unstructured":"Ito, H., Esashi, E., Akiyama, T., Inoue, J.-i & Miyajima, A. IL-18 produced by thymic epithelial cells induces development of dendritic cells with CD11b in the fetal thymus. Int. Immunol. 18, 1253\u20131263 (2006).","journal-title":"Int. Immunol."},{"key":"1330_CR77","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/329157a0","volume":"329","author":"RP Shimonkevitz","year":"1987","unstructured":"Shimonkevitz, R. P., Husmann, L. A., Bevan, M. J. & Crispe, I. N. Transient expression of IL-2 receptor precedes the differentiation of immature thymocytes. Nature 329, 157\u2013159 (1987).","journal-title":"Nature"},{"key":"1330_CR78","doi-asserted-by":"publisher","first-page":"qiae172","DOI":"10.1093\/jleuko\/qiae172","volume":"117","author":"W Li","year":"2024","unstructured":"Li, W. et al. IL-18 primes T cells with an antigen-inexperienced memory phenotype for proliferation and differentiation into effector cells through Notch signaling. J. Leukoc. Biol. 117, qiae172 (2024).","journal-title":"J. Leukoc. Biol."},{"key":"1330_CR79","doi-asserted-by":"publisher","first-page":"1278521","DOI":"10.3389\/fimmu.2023.1278521","volume":"14","author":"M Gu","year":"2023","unstructured":"Gu, M. et al. Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front. Immunol. 14, 1278521 (2023).","journal-title":"Front. Immunol."},{"key":"1330_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","volume":"4","author":"MH Kaplan","year":"1996","unstructured":"Kaplan, M. H., Schindler, U., Smiley, S. T. & Grusby, M. J. Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells. Immunity 4, 313\u2013319 (1996).","journal-title":"Immunity"},{"key":"1330_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101975","volume":"24","author":"W Liao","year":"2021","unstructured":"Liao, W. et al. The downregulation of IL-18R defines bona fide kidney-resident CD8+ T cells. iScience 24, 101975 (2021).","journal-title":"iScience"},{"key":"1330_CR82","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002273","volume":"7","author":"JT Ingram","year":"2011","unstructured":"Ingram, J. T., Yi, J. S. & Zajac, A. J. Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog. 7, e1002273 (2011).","journal-title":"PLoS Pathog."},{"key":"1330_CR83","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.immuni.2009.09.015","volume":"31","author":"CJ Turtle","year":"2009","unstructured":"Turtle, C. J., Swanson, H. M., Fujii, N., Estey, E. H. & Riddell, S. R. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity 31, 834\u2013844 (2009).","journal-title":"Immunity"},{"key":"1330_CR84","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","volume":"23","author":"MP Avanzi","year":"2018","unstructured":"Avanzi, M. P. et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 23, 2130\u20132141 (2018).","journal-title":"Cell Rep."},{"key":"1330_CR85","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00262-022-03197-2","volume":"71","author":"B Zangari","year":"2022","unstructured":"Zangari, B. et al. Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol. Immunother. 71, 2881\u20132898 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"1330_CR86","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13045-023-01504-7","volume":"16","author":"Y Bulliard","year":"2023","unstructured":"Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. & Tsimberidou, A. M. Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy. J. Hematol. Oncol. 16, 108 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"1330_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.2020009309","volume":"138","author":"W Zheng","year":"2021","unstructured":"Zheng, W. et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR\u2013T-cell responses against ALL. Blood 138, 122\u2013135 (2021).","journal-title":"Blood"},{"key":"1330_CR88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2218632120","volume":"120","author":"D Mai","year":"2023","unstructured":"Mai, D. et al. Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. Proc. Natl Acad. Sci. USA 120, e2218632120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR89","doi-asserted-by":"publisher","first-page":"426","DOI":"10.4049\/jimmunol.171.1.426","volume":"171","author":"N Takeda","year":"2003","unstructured":"Takeda, N. et al. Bcl6 is a transcriptional repressor for the IL-18 gene. J. Immunol. 171, 426\u2013431 (2003).","journal-title":"J. Immunol."},{"key":"1330_CR90","doi-asserted-by":"publisher","first-page":"5088","DOI":"10.4049\/jimmunol.0801613","volume":"182","author":"G Alsaleh","year":"2009","unstructured":"Alsaleh, G. et al. Bruton\u2019s tyrosine kinase is involved in miR-346-related regulation of IL-18 release by lipopolysaccharide-activated rheumatoid fibroblast-like synoviocytes. J. Immunol. 182, 5088\u20135097 (2009).","journal-title":"J. Immunol."},{"key":"1330_CR91","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1172\/JCI128322","volume":"130","author":"L Mao","year":"2020","unstructured":"Mao, L. et al. Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1\u03b2-mediated colitis. J. Clin. Invest. 130, 1793\u20131807 (2020).","journal-title":"J. Clin. Invest."},{"key":"1330_CR92","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3389\/fmicb.2018.01019","volume":"9","author":"A Diotallevi","year":"2018","unstructured":"Diotallevi, A. et al. Leishmania infection induces microRNA hsa-miR-346 in human cell line-derived macrophages. Front. Microbiol. 9, 1019 (2018).","journal-title":"Front. Microbiol."},{"key":"1330_CR93","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/386619a0","volume":"386","author":"T Ghayur","year":"1997","unstructured":"Ghayur, T. et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386, 619\u2013623 (1997).","journal-title":"Nature"},{"key":"1330_CR94","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1126\/science.275.5297.206","volume":"275","author":"Y Gu","year":"1997","unstructured":"Gu, Y. et al. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275, 206\u2013209 (1997).","journal-title":"Science"},{"key":"1330_CR95","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417\u2013426 (2002).","journal-title":"Mol. Cell"},{"key":"1330_CR96","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/ni.1703","volume":"10","author":"L Franchi","year":"2009","unstructured":"Franchi, L., Eigenbrod, T., Mu\u00f1oz-Planillo, R. & Nu\u00f1ez, G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241\u2013247 (2009).","journal-title":"Nat. Immunol."},{"key":"1330_CR97","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molmed.2016.12.007","volume":"23","author":"MN Patel","year":"2017","unstructured":"Patel, M. N. et al. Inflammasome priming in sterile inflammatory disease. Trends Mol. Med. 23, 165\u2013180 (2017).","journal-title":"Trends Mol. Med."},{"key":"1330_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113581","volume":"42","author":"PM Exconde","year":"2023","unstructured":"Exconde, P. M. et al. The tetrapeptide sequence of IL-18 and IL-1\u03b2 regulates their recruitment and activation by inflammatory caspases. Cell Rep. 42, 113581 (2023).","journal-title":"Cell Rep."},{"key":"1330_CR99","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.4049\/jimmunol.1202121","volume":"189","author":"L Bossaller","year":"2012","unstructured":"Bossaller, L. et al. Cutting edge: FAS (CD95) mediates noncanonical IL-1\u03b2 and IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol. 189, 5508\u20135512 (2012).","journal-title":"J. Immunol."},{"key":"1330_CR100","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/eji.200535402","volume":"36","author":"SE Robertson","year":"2006","unstructured":"Robertson, S. E. et al. Expression and alternative processing of IL-18 inhuman neutrophils. Eur. J. Immunol. 36, 722\u2013731 (2006).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR101","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.4049\/jimmunol.1601223","volume":"198","author":"Z Fu","year":"2017","unstructured":"Fu, Z. et al. Highly selective cleavage of cytokines and chemokines by the human mast cell chymase and neutrophil cathepsin G. J. Immunol. 198, 1474\u20131483 (2017).","journal-title":"J. Immunol."},{"key":"1330_CR102","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1073\/pnas.94.8.3948","volume":"94","author":"T Yoshimoto","year":"1997","unstructured":"Yoshimoto, T., Okamura, H., Tagawa, Y.-I., Iwakura, Y. & Nakanishi, K. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-\u03b3 production from activated B cells. Proc. Natl Acad. Sci. USA 94, 3948\u20133953 (1997). IL-18 together with IL-12 inhibits IgE production by induction of IFN\u03b3 production from activated B cells.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR103","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.imlet.2005.05.008","volume":"101","author":"K Mizuno","year":"2005","unstructured":"Mizuno, K. et al. \u03b22-adrenergic receptor stimulation inhibits LPS-induced IL-18 and IL-12 production in monocytes. Immunol. Lett. 101, 168\u2013172 (2005).","journal-title":"Immunol. Lett."},{"key":"1330_CR104","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/sj.cgt.7700964","volume":"13","author":"L Vujanovic","year":"2006","unstructured":"Vujanovic, L. et al. IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Cancer Gene Ther. 13, 798\u2013805 (2006).","journal-title":"Cancer Gene Ther."},{"key":"1330_CR105","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/ard.2003.018481","volume":"63","author":"S-M Dai","year":"2004","unstructured":"Dai, S.-M., Nishioka, K. & Yudoh, K. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1\u03b2 and tumour necrosis factor \u03b1. Ann. Rheum. Dis. 63, 1379\u20131386 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"1330_CR106","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.4049\/jimmunol.166.8.4915","volume":"166","author":"NJ Horwood","year":"2001","unstructured":"Horwood, N. J., Elliott, J., Martin, T. J. & Gillespie, M. T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 166, 4915\u20134921 (2001).","journal-title":"J. Immunol."},{"key":"1330_CR107","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00403-017-1735-2","volume":"309","author":"N Shimoura","year":"2017","unstructured":"Shimoura, N. et al. Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia. Arch. Dermatol. Res. 309, 315\u2013321 (2017).","journal-title":"Arch. Dermatol. Res."},{"key":"1330_CR108","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.2147\/JIR.S329528","volume":"14","author":"Y Chen","year":"2021","unstructured":"Chen, Y. et al. The effects of adoptively transferred IL-23\/IL-18-polarized neutrophils on tumor and collagen-induced arthritis in mice. J. Inflamm. Res. 14, 4669\u20134686 (2021).","journal-title":"J. Inflamm. Res."},{"key":"1330_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1479505","volume":"15","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. The role of interleukin-17 in inflammation-related cancers. Front. Immunol. 15, 1479505 (2024).","journal-title":"Front. Immunol."},{"key":"1330_CR110","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3389\/fimmu.2017.01959","volume":"8","author":"A Ziblat","year":"2018","unstructured":"Ziblat, A. et al. Interleukin (IL)-23 stimulates IFN-\u03b3 secretion by CD56bright natural killer cells and enhances IL-18-driven dendritic cells activation. Front. Immunol. 8, 1959 (2018).","journal-title":"Front. Immunol."},{"key":"1330_CR111","doi-asserted-by":"publisher","first-page":"4611","DOI":"10.1158\/1078-0432.CCR-13-0568","volume":"19","author":"G Carbotti","year":"2013","unstructured":"Carbotti, G. et al. The IL-18 antagonist IL-18\u2013binding protein is produced in the human ovarian cancer microenvironment. Clin. Cancer Res. 19, 4611\u20134620 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1330_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038751","volume":"7","author":"M Wittmann","year":"2012","unstructured":"Wittmann, M. et al. IL-27 regulates IL-18 binding protein in skin resident cells. PLoS ONE 7, e38751 (2012).","journal-title":"PLoS ONE"},{"key":"1330_CR113","doi-asserted-by":"publisher","first-page":"6135","DOI":"10.1038\/s41467-025-61196-0","volume":"16","author":"V Picant","year":"2025","unstructured":"Picant, V. et al. Interleukin-35 impairs human NK cell effector functions and induces their ILC1-like conversion with tissue residency features. Nat. Commun. 16, 6135 (2025).","journal-title":"Nat. Commun."},{"key":"1330_CR114","first-page":"1251","volume":"19","author":"M Zhu","year":"2020","unstructured":"Zhu, M., Rong, X., Li, M. & Wang, S. IL-18 and IL-35 in the serum of patients with sepsis thrombocytopenia and the clinical significance. Exp. Ther. Med. 19, 1251\u20131258 (2020).","journal-title":"Exp. Ther. Med."},{"key":"1330_CR115","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2016.10.016","volume":"90","author":"O Allam","year":"2017","unstructured":"Allam, O. et al. Differential synthesis and release of IL-18 and IL-18 binding protein from human platelets and their implications for HIV infection. Cytokine 90, 144\u2013154 (2017).","journal-title":"Cytokine"},{"key":"1330_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100263","volume":"10","author":"X Cui","year":"2025","unstructured":"Cui, X. et al. IL-12 family cytokines and autoimmune diseases: a potential therapeutic target? J. Transl. Autoimmun. 10, 100263 (2025).","journal-title":"J. Transl. Autoimmun."},{"key":"1330_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28478-3","volume":"13","author":"H-Y Chiang","year":"2022","unstructured":"Chiang, H.-Y. et al. IL-22 initiates an IL-18-dependent epithelial response circuit to enforce intestinal host defence. Nat. Commun. 13, 874 (2022).","journal-title":"Nat. Commun."},{"key":"1330_CR118","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.immuni.2015.01.011","volume":"42","author":"M Mu\u00f1oz","year":"2015","unstructured":"Mu\u00f1oz, M. et al. Interleukin-22 induces interleukin-18 expression from epithelial cells during intestinal infection. Immunity 42, 321\u2013331 (2015).","journal-title":"Immunity"},{"key":"1330_CR119","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","volume":"131","author":"ES Weiss","year":"2018","unstructured":"Weiss, E. S. et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood 131, 1442\u20131455 (2018).","journal-title":"Blood"},{"key":"1330_CR120","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nature11535","volume":"491","author":"S Huber","year":"2012","unstructured":"Huber, S. et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259\u2013263 (2012).\u00a0IL-18 modulates intestinal IL-22 supply by downregulating IL-22BP, with reciprocal IL-22\/IL-22BP and IL-18\/IL-18BP interactions acting as crucial switches between protective and\u00a0tumorigenic responses.","journal-title":"Nature"},{"key":"1330_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/ar3295","volume":"13","author":"S Takei","year":"2011","unstructured":"Takei, S. et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res. Ther. 13, R52 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1330_CR122","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1006\/cyto.2001.0914","volume":"14","author":"D Novick","year":"2001","unstructured":"Novick, D. et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 14, 334\u2013342 (2001).","journal-title":"Cytokine"},{"key":"1330_CR123","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/vim.2009.0077","volume":"23","author":"C Chirathaworn","year":"2010","unstructured":"Chirathaworn, C., Rianthavorn, P., Wuttirattanakowit, N. & Poovorawan, Y. Serum IL-18 and IL-18BP levels in patients with chikungunya virus infection. Viral Immunol. 23, 113\u2013117 (2010).","journal-title":"Viral Immunol."},{"key":"1330_CR124","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1046\/j.1365-2249.2002.01911.x","volume":"129","author":"A Kaser","year":"2002","unstructured":"Kaser, A. et al. Interferon-\u03b1 induces interleukin-18 binding protein in chronic hepatitis C patients. Clin. Exp. Immunol. 129, 332\u2013338 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"1330_CR125","doi-asserted-by":"publisher","first-page":"11125","DOI":"10.3390\/ijms241311125","volume":"24","author":"C Baggio","year":"2023","unstructured":"Baggio, C. et al. IL-18 in autoinflammatory diseases: focus on adult onset still disease and macrophages activation syndrome. Int. J. Mol. Sci. 24, 11125 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1330_CR126","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.4049\/jimmunol.168.5.2282","volume":"168","author":"KG Veenstra","year":"2002","unstructured":"Veenstra, K. G., Jonak, Z. L., Trulli, S. & Gollob, J. A. IL-12 induces monocyte IL-18 binding protein expression via IFN-gamma. J. Immunol. 168, 2282\u20132287 (2002).","journal-title":"J. Immunol."},{"key":"1330_CR127","doi-asserted-by":"publisher","first-page":"7038","DOI":"10.4049\/jimmunol.167.12.7038","volume":"167","author":"J Paulukat","year":"2001","unstructured":"Paulukat, J. et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J. Immunol. 167, 7038\u20137043 (2001).","journal-title":"J. Immunol."},{"key":"1330_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-005388","volume":"11","author":"C Girard-Guyonvarc\u2019h","year":"2025","unstructured":"Girard-Guyonvarc\u2019h, C. et al. Elevated serum levels of interleukin-18 discriminate Still\u2019s disease from other autoinflammatory conditions: results from the European ImmunAID cohort. RMD Open 11, e005388 (2025).","journal-title":"RMD Open"},{"key":"1330_CR129","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","volume":"106","author":"K Mazodier","year":"2005","unstructured":"Mazodier, K. et al. Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 106, 3483\u20133489 (2005).","journal-title":"Blood"},{"key":"1330_CR130","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbi.2021.10.017","volume":"99","author":"A Szabo","year":"2022","unstructured":"Szabo, A. et al. Increased circulating IL-18 levels in severe mental disorders indicate systemic inflammasome activation. Brain Behav. Immun. 99, 299\u2013306 (2022). IL-18 and IL-18BP ratios are dysregulated in neuropsychiatric disorders suggesting immunomodulatory approaches probably have value in treating the same.","journal-title":"Brain Behav. Immun."},{"key":"1330_CR131","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1471-4906(01)02034-8","volume":"22","author":"E Dunn","year":"2001","unstructured":"Dunn, E., Sims, J. E., Nicklin, M. J. H. & O\u2019Neill, L. A. J. Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol. 22, 533\u2013536 (2001).","journal-title":"Trends Immunol."},{"key":"1330_CR132","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/S1471-4906(01)02040-3","volume":"22","author":"JE Sims","year":"2001","unstructured":"Sims, J. E. et al. A new nomenclature for IL-1-family genes. Trends Immunol. 22, 536\u2013537 (2001).","journal-title":"Trends Immunol."},{"key":"1330_CR133","doi-asserted-by":"publisher","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","volume":"275","author":"S Kumar","year":"2000","unstructured":"Kumar, S. et al. Identification and initial characterization of four novel members of the interleukin-1 family. J. Biol. Chem. 275, 10308\u201310314 (2000).","journal-title":"J. Biol. Chem."},{"key":"1330_CR134","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1002\/1521-4141(200011)30:11<3299::AID-IMMU3299>3.0.CO;2-S","volume":"30","author":"JL Barton","year":"2000","unstructured":"Barton, J. L., Herbst, R., Bosisio, D., Higgins, L. & Nicklin, M. J. H. A tissue specific IL-1 receptor antagonist homolog from the IL-1 cluster lacks IL-1, IL-1ra, IL-18 and IL-18 antagonist activities. Eur. J. Immunol. 30, 3299\u20133308 (2000).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR135","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1006\/cyto.2002.0873","volume":"18","author":"S Kumar","year":"2002","unstructured":"Kumar, S. et al. Interleukin-1F7B (IL-1H4\/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-\u03b3 production. Cytokine 18, 61\u201371 (2002).","journal-title":"Cytokine"},{"key":"1330_CR136","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1126\/science.1254803","volume":"346","author":"S Ariotti","year":"2014","unstructured":"Ariotti, S. et al. T cell memory. Skin-resident memory CD8+ T cells trigger a state of tissue-wide pathogen alert. Science 346, 101\u2013105 (2014).","journal-title":"Science"},{"key":"1330_CR137","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ni.1866","volume":"11","author":"G Perona-Wright","year":"2010","unstructured":"Perona-Wright, G., Mohrs, K. & Mohrs, M. Sustained signaling by canonical helper T cell cytokines throughout the reactive lymph node. Nat. Immunol. 11, 520\u2013526 (2010).","journal-title":"Nat. Immunol."},{"key":"1330_CR138","doi-asserted-by":"publisher","first-page":"13723","DOI":"10.1073\/pnas.212519099","volume":"99","author":"P Bufler","year":"2002","unstructured":"Bufler, P. et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc. Natl Acad. Sci. USA 99, 13723\u201313728 (2002). IL-37 and IL-18BP can bind each other to suppress IFN\u03b3 responses, yet the reciprocal regulatory axes between IL-37 and IL-18BP remain unknown.","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR139","doi-asserted-by":"publisher","first-page":"108952","DOI":"10.1016\/j.jmgm.2025.108952","volume":"136","author":"I Sardag","year":"2025","unstructured":"Sardag, I., Duvenci, Z. S., Belkaya, S. & Timucin, E. Computational modeling of the anti-inflammatory complexes of IL37. J. Mol. Graph. Model. 136, 108952 (2025).","journal-title":"J. Mol. Graph. Model."},{"key":"1330_CR140","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.4049\/jimmunol.170.4.2100","volume":"170","author":"NK Banda","year":"2003","unstructured":"Banda, N. K. et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J. Immunol. 170, 2100\u20132105 (2003).","journal-title":"J. Immunol."},{"key":"1330_CR141","doi-asserted-by":"publisher","first-page":"696605","DOI":"10.3389\/fimmu.2021.696605","volume":"12","author":"Z Su","year":"2021","unstructured":"Su, Z. & Tao, X. Current understanding of IL-37 in human health and disease. Front. Immunol. 12, 696605 (2021).","journal-title":"Front. Immunol."},{"key":"1330_CR142","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1006\/geno.2002.6752","volume":"79","author":"SL Taylor","year":"2002","unstructured":"Taylor, S. L., Renshaw, B. R., Garka, K. E., Smith, D. E. & Sims, J. E. Genomic organization of the interleukin-1 locus. Genomics 79, 726\u2013733 (2002).","journal-title":"Genomics"},{"key":"1330_CR143","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/165742","volume":"2014","author":"Q Ji","year":"2014","unstructured":"Ji, Q. et al. Elevated plasma IL-37, IL-18, and IL-18BP concentrations in patients with acute coronary syndrome. Mediat. Inflamm. 2014, 165742 (2014).","journal-title":"Mediat. Inflamm."},{"key":"1330_CR144","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.31557\/APJCP.2022.23.8.2851","volume":"23","author":"MR Haghshenas","year":"2022","unstructured":"Haghshenas, M. R. et al. Simultaneous increase in serum levels of IL-37 and IL-18 binding protein in low-grade and high-grade brain tumors. Asian Pac. J. Cancer Prev. 23, 2851\u20132856 (2022).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"1330_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05623-8","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. High-dose IL-37 promotes inflammatory activity of macrophage via preferential ligation of the IL-18R\u03b1. Sci. Rep. 15, 22396 (2025).","journal-title":"Sci. Rep."},{"key":"1330_CR146","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1073\/pnas.1819672116","volume":"116","author":"EZ Eisenmesser","year":"2019","unstructured":"Eisenmesser, E. Z. et al. Interleukin-37 monomer is the active form for reducing innate immunity. Proc. Natl Acad. Sci. USA 116, 5514\u20135522 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR147","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aaj1548","volume":"2","author":"AM Ellisdon","year":"2017","unstructured":"Ellisdon, A. M. et al. Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Sci. Immunol. 2, eaaj1548 (2017).","journal-title":"Sci. Immunol."},{"key":"1330_CR148","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.1944","volume":"11","author":"MF Nold","year":"2010","unstructured":"Nold, M. F. et al. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11, 1014\u20131022 (2010). The SMAD3-dependent anti-inflammatory programme of intracellular IL-37 is described in human and mouse cells.","journal-title":"Nat. Immunol."},{"key":"1330_CR149","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ni.3103","volume":"16","author":"CA Nold-Petry","year":"2015","unstructured":"Nold-Petry, C. A. et al. IL-37 requires the receptors IL-18R\u03b1 and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat. Immunol. 16, 354\u2013365 (2015). Extracellular IL-37 recruits IL-1R8 and IL-18R\u03b1 to initiate an anti-inflammatory signalling programme by modulating cellular metabolism and signal transduction.","journal-title":"Nat. Immunol."},{"key":"1330_CR150","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.bbalip.2019.05.009","volume":"1864","author":"T Liu","year":"2019","unstructured":"Liu, T. et al. IL-37 inhibits the maturation of dendritic cells through the IL-1R8-TLR4-NF-\u03baB pathway. Biochim. Biophys. Acta 1864, 1338\u20131349 (2019).","journal-title":"Biochim. Biophys. Acta"},{"key":"1330_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22617-y","volume":"12","author":"L Sun","year":"2022","unstructured":"Sun, L., Yuan, H. & Zhao, G. IL-37 alleviates Coxsackievirus B3-induced viral myocarditis via inhibiting NLRP3 inflammasome-mediated pyroptosis. Sci. Rep. 12, 20077 (2022).","journal-title":"Sci. Rep."},{"key":"1330_CR152","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/imr.12605","volume":"281","author":"G Cavalli","year":"2018","unstructured":"Cavalli, G. & Dinarello, C. A. Suppression of inflammation and acquired immunity by IL-37. Immunol. Rev. 281, 179\u2013190 (2018).","journal-title":"Immunol. Rev."},{"key":"1330_CR153","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.imbio.2015.09.009","volume":"221","author":"R Charrad","year":"2016","unstructured":"Charrad, R. et al. Anti-inflammatory activity of IL-37 in asthmatic children: correlation with inflammatory cytokines TNF-\u03b1, IL-\u03b2, IL-6 and IL-17A. Immunobiology 221, 182\u2013187 (2016).","journal-title":"Immunobiology"},{"key":"1330_CR154","doi-asserted-by":"publisher","first-page":"101952","DOI":"10.1016\/j.smim.2025.101952","volume":"78","author":"Y Li","year":"2025","unstructured":"Li, Y., Chen, N., Guo, Y. & Zhang, L. The stress and the alarmin-like cytokine interleukin-37 mediated extracellular and intracellular signal pathways. Semin. Immunol. 78, 101952 (2025).","journal-title":"Semin. Immunol."},{"key":"1330_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107072","volume":"200","author":"D Wang","year":"2024","unstructured":"Wang, D. et al. Agree to disagree: the contradiction between IL-18 and IL-37 reveals shared targets in cancer. Pharmacol. Res. 200, 107072 (2024).","journal-title":"Pharmacol. Res."},{"key":"1330_CR156","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","volume":"100","author":"SJ Szabo","year":"2000","unstructured":"Szabo, S. J. et al. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100, 655\u2013669 (2000).","journal-title":"Cell"},{"key":"1330_CR157","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.1073\/pnas.2636938100","volume":"100","author":"BM Sullivan","year":"2003","unstructured":"Sullivan, B. M., Juedes, A., Szabo, S. J., von Herrath, M. & Glimcher, L. H. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc. Natl Acad. Sci. USA 100, 15818\u201315823 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR158","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1073\/pnas.261570598","volume":"98","author":"AA Lighvani","year":"2001","unstructured":"Lighvani, A. A. et al. T-bet is rapidly induced by interferon-\u03b3 in lymphoid and myeloid cells. Proc. Natl Acad. Sci. USA 98, 15137\u201315142 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR159","doi-asserted-by":"publisher","first-page":"102299","DOI":"10.1016\/j.coi.2023.102299","volume":"82","author":"D Paprckova","year":"2023","unstructured":"Paprckova, D., Salyova, E., Michalik, J. & Stepanek, O. Bystander activation in memory and antigen-inexperienced memory-like CD8 T cells. Curr. Opin. Immunol. 82, 102299 (2023).","journal-title":"Curr. Opin. Immunol."},{"key":"1330_CR160","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1073\/pnas.1332767100","volume":"100","author":"G Lugo-Villarino","year":"2003","unstructured":"Lugo-Villarino, G., Maldonado-Lopez, R., Possemato, R., Penaranda, C. & Glimcher, L. H. T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proc. Natl Acad. Sci. USA 100, 7749\u20137754 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR161","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000247156","volume":"2","author":"CM Robinson","year":"2009","unstructured":"Robinson, C. M., O\u2019Dee, D., Hamilton, T. & Nau, G. J. Cytokines involved in interferon-\u03b3 production by human macrophages. J. Innate Immun. 2, 56\u201365 (2009).","journal-title":"J. Innate Immun."},{"key":"1330_CR162","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1615\/CritRevImmunol.2016017387","volume":"36","author":"AY Mah","year":"2016","unstructured":"Mah, A. Y. & Cooper, M. A. Metabolic regulation of natural killer cell IFN-\u03b3 production. Crit. Rev. Immunol. 36, 131\u2013147 (2016).","journal-title":"Crit. Rev. Immunol."},{"key":"1330_CR163","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.4049\/jimmunol.1800537","volume":"201","author":"A Sharma","year":"2018","unstructured":"Sharma, A. et al. LFA-1 ligation by high-density ICAM-1 is sufficient to activate IFN-\u03b3 release by innate T lymphocytes. J. Immunol. 201, 2452\u20132461 (2018).","journal-title":"J. Immunol."},{"key":"1330_CR164","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1074-7613(00)80378-7","volume":"7","author":"D Robinson","year":"1997","unstructured":"Robinson, D. et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-gamma production and activates IRAK and NFkappaB. Immunity 7, 571\u2013581 (1997).","journal-title":"Immunity"},{"key":"1330_CR165","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.immuni.2009.03.013","volume":"30","author":"EG Schulz","year":"2009","unstructured":"Schulz, E. G., Mariani, L., Radbruch, A. & H\u00f6fer, T. Sequential polarization and imprinting of type 1 T helper lymphocytes by interferon-\u03b3 and interleukin-12. Immunity 30, 673\u2013683 (2009).","journal-title":"Immunity"},{"key":"1330_CR166","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1172\/JCI12466","volume":"108","author":"Z Han","year":"2001","unstructured":"Han, Z. et al. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin. Invest. 108, 73\u201381 (2001).","journal-title":"J. Clin. Invest."},{"key":"1330_CR167","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.4049\/jimmunol.181.5.3346","volume":"181","author":"Q Yu","year":"2008","unstructured":"Yu, Q., Chang, H. C., Ahyi, A. N. & Kaplan, M. H. Transcription factor-dependent chromatin remodeling of Il18r1 during Th1 and Th2 differentiation. J. Immunol. 181, 3346\u20133352 (2008).","journal-title":"J. Immunol."},{"key":"1330_CR168","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2006-11-058271","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang, Y., Ochando, J. C., Bromberg, J. S. & Ding, Y. Identification of a distant T-bet enhancer responsive to IL-12\/Stat4 and IFN\u03b3\/Stat1 signals. Blood 110, 2494\u20132500 (2007).","journal-title":"Blood"},{"key":"1330_CR169","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1101\/gad.1689708","volume":"22","author":"SA Miller","year":"2008","unstructured":"Miller, S. A., Huang, A. C., Miazgowicz, M. M., Brassil, M. M. & Weinmann, A. S. Coordinated but physically separable interaction with H3K27-demethylase and H3K4-methyltransferase activities are required for T-box protein-mediated activation of developmental gene expression. Genes Dev. 22, 2980\u20132993 (2008). A detailed examination of T-bet induction at the molecular and epigenetic level.","journal-title":"Genes Dev."},{"key":"1330_CR170","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158\u2013172 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1330_CR171","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","volume":"11","author":"D Alizadeh","year":"2021","unstructured":"Alizadeh, D. et al. IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Cancer Discov. 11, 2248\u20132265 (2021).","journal-title":"Cancer Discov."},{"key":"1330_CR172","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1158\/0008-5472.CAN-19-0596","volume":"79","author":"M Song","year":"2019","unstructured":"Song, M. et al. Low-dose IFN\u03b3 induces tumor cell stemness in tumor microenvironment of non\u2013small cell lung cancer. Cancer Res. 79, 3737\u20133748 (2019).","journal-title":"Cancer Res."},{"key":"1330_CR173","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","volume":"1","author":"R Thibaut","year":"2020","unstructured":"Thibaut, R. et al. Bystander IFN-\u03b3 activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment. Nat. Cancer 1, 302\u2013314 (2020). An elegant paper stressing the importance of spatiotemporal distribution of cytokines within the TME.","journal-title":"Nat. Cancer"},{"key":"1330_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00925-6","volume":"8","author":"M Gordon-Alonso","year":"2017","unstructured":"Gordon-Alonso, M., Hirsch, T., Wildmann, C. & van der Bruggen, P. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration. Nat. Commun. 8, 793 (2017).","journal-title":"Nat. Commun."},{"key":"1330_CR175","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.semcancer.2022.03.011","volume":"86","author":"Y Yang","year":"2022","unstructured":"Yang, Y. & Cao, Y. The impact of VEGF on cancer metastasis and systemic disease. Semin. Cancer Biol. 86, 251\u2013261 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"1330_CR176","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1182\/blood-2002-07-1956","volume":"101","author":"JE Ohm","year":"2003","unstructured":"Ohm, J. E. et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101, 4878\u20134886 (2003).","journal-title":"Blood"},{"key":"1330_CR177","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jcp.24575","volume":"229","author":"J Shen","year":"2014","unstructured":"Shen, J. et al. Interleukin-18 has antipermeablity and antiangiogenic activities in the eye: reciprocal suppression with VEGF. J. Cell Physiol. 229, 974\u2013983 (2014).","journal-title":"J. Cell Physiol."},{"key":"1330_CR178","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/sj.onc.1209926","volume":"26","author":"KE Kim","year":"2007","unstructured":"Kim, K. E. et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26, 1468\u20131476 (2007).","journal-title":"Oncogene"},{"key":"1330_CR179","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1093\/carcin\/bgp158","volume":"30","author":"JS Kang","year":"2009","unstructured":"Kang, J. S. et al. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis 30, 1987\u20131996 (2009).","journal-title":"Carcinogenesis"},{"key":"1330_CR180","first-page":"4105","volume":"57","author":"S Scherbarth","year":"1997","unstructured":"Scherbarth, S. & Orr, F. W. Intravital videomicroscopic evidence for regulation of metastasis by the hepatic microvasculature: effects of interleukin-1\u03b1 on metastasis and the location of B16F1 melanoma cell arrest. Cancer Res. 57, 4105\u20134110 (1997).","journal-title":"Cancer Res."},{"key":"1330_CR181","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-11-2904","volume":"18","author":"Q Chen","year":"2012","unstructured":"Chen, Q. & Massagu\u00e9, J. Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin. Cancer Res. 18, 5520\u20135525 (2012).","journal-title":"Clin. Cancer Res."},{"key":"1330_CR182","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3389\/fonc.2020.01066","volume":"10","author":"D Zhang","year":"2020","unstructured":"Zhang, D. et al. VCAM1 promotes tumor cell invasion and metastasis by inducing EMT and transendothelial migration in colorectal cancer. Front. Oncol. 10, 1066 (2020).","journal-title":"Front. Oncol."},{"key":"1330_CR183","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.suronc.2019.12.001","volume":"32","author":"L Ding","year":"2020","unstructured":"Ding, L. et al. The balance of serum IL-18\/IL-37 levels is disrupted during the development of oral squamous cell carcinoma. Surg. Oncol. 32, 99\u2013107 (2020).","journal-title":"Surg. Oncol."},{"key":"1330_CR184","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay, C. et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann. Rheum. Dis. 77, 840\u2013847 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"1330_CR185","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semcdb.2015.01.015","volume":"39","author":"S Latour","year":"2015","unstructured":"Latour, S. & Aguilar, C. XIAP deficiency syndrome in humans. Semin. Cell Dev. Biol. 39, 115\u2013123 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"1330_CR186","volume":"11","author":"DA Witherden","year":"2023","unstructured":"Witherden, D. A. et al. 1076 discovery and evaluation of an anti-IL18BP antibody to enhance anti-tumor immunity. J. Immunother. Cancer 11, A1185 (2023). Anti-IL-18BP monoclonal antibody prevents IL-18 capture by IL-18BP and leads to superior IFN\u03b3 responses in tumour models.","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR187","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100978","volume":"4","author":"I Olivera","year":"2023","unstructured":"Olivera, I. et al. mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy. Cell Rep. Med. 4, 100978 (2023).","journal-title":"Cell Rep. Med."},{"key":"1330_CR188","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609\u2013614 (2020). Engineered decoy-resistant IL-18 escapes IL-18BP-mediated suppression and markedly improves CTL performance.","journal-title":"Nature"},{"key":"1330_CR189","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1111\/bph.12584","volume":"171","author":"RC Lima-J\u00fanior","year":"2014","unstructured":"Lima-J\u00fanior, R. C. et al. Targeted inhibition of IL-18 attenuates irinotecan-induced intestinal mucositis in mice. Br. J. Pharmacol. 171, 2335\u20132350 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"1330_CR190","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/2326-6066.CIR-23-0706","volume":"12","author":"A Menachem","year":"2024","unstructured":"Menachem, A. et al. Unleashing natural IL18 activity using an anti-IL18BP blocker induces potent immune stimulation and antitumor effects. Cancer Immunol. Res. 12, 687\u2013703 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1330_CR191","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/JLB.3MA0220-207RR","volume":"107","author":"Y Mei","year":"2020","unstructured":"Mei, Y. et al. The indirect antiangiogenic effect of IL-37 in the tumor microenvironment. J. Leukoc. Biol. 107, 783\u2013796 (2020).","journal-title":"J. Leukoc. Biol."},{"key":"1330_CR192","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13046-016-0293-3","volume":"35","author":"G Ge","year":"2016","unstructured":"Ge, G. et al. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J. Exp. Clin. Cancer Res. 35, 13 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1330_CR193","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.2147\/CMAR.S200627","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. IL-37 induces anti-tumor immunity by indirectly promoting dendritic cell recruitment and activation in hepatocellular carcinoma. Cancer Manag. Res. 11, 6691\u20136702 (2019).","journal-title":"Cancer Manag. Res."},{"key":"1330_CR194","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molimm.2020.03.012","volume":"122","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z., Zhang, J., He, P., Han, J. & Sun, C. Interleukin-37 suppresses hepatocellular carcinoma growth through inhibiting M2 polarization of tumor-associated macrophages. Mol. Immunol. 122, 13\u201320 (2020).","journal-title":"Mol. Immunol."},{"key":"1330_CR195","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2326-6066.CIR-17-0498","volume":"6","author":"D Sarhan","year":"2018","unstructured":"Sarhan, D. et al. Adaptive NK cells resist regulatory T-cell suppression driven by IL37. Cancer Immunol. Res. 6, 766\u2013775 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1330_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.113835","volume":"43","author":"Y Mei","year":"2024","unstructured":"Mei, Y. et al. IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Cell Rep. 43, 113835 (2024).","journal-title":"Cell Rep."},{"key":"1330_CR197","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13309","volume":"20","author":"JAG Hamilton","year":"2021","unstructured":"Hamilton, J. A. G. et al. Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Aging Cell 20, e13309 (2021).","journal-title":"Aging Cell"},{"key":"1330_CR198","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187\u20132194 (2010).","journal-title":"J. Exp. Med."},{"key":"1330_CR199","doi-asserted-by":"publisher","first-page":"32722","DOI":"10.18632\/oncotarget.16281","volume":"8","author":"IH Park","year":"2017","unstructured":"Park, I. H. et al. Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer. Oncotarget 8, 32722\u201332730 (2017).","journal-title":"Oncotarget"},{"key":"1330_CR200","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","volume":"71","author":"M Terme","year":"2011","unstructured":"Terme, M. et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71, 5393\u20135399 (2011).","journal-title":"Cancer Res."},{"key":"1330_CR201","doi-asserted-by":"publisher","first-page":"1718321","DOI":"10.3389\/fimmu.2025.1718321","volume":"16","author":"X Zhou","year":"2025","unstructured":"Zhou, X., Geyer, F. K., Takimoto, J., Kolmar, H. & Rabinovich, B. Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activity. Front. Immunol. 16, 1718321 (2025).","journal-title":"Front. Immunol."},{"key":"1330_CR202","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-sitc2024.0958","author":"X Zhou","year":"2024","unstructured":"Zhou, X., Takimoto, J., Yoon, S. & Rabinovich, B. 958 targeting functionally specific IL-18 (F-18) to PD-1: a next generation checkpoint inhibitor with enhanced anti-tumor activity. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2024-sitc2024.0958 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR203","doi-asserted-by":"publisher","DOI":"10.1038\/srep14478","volume":"5","author":"X Shuai","year":"2015","unstructured":"Shuai, X. et al. Expression of IL-37 contributes to the immunosuppressive property of human CD4+CD25+ regulatory T cells. Sci. Rep. 5, 14478 (2015).","journal-title":"Sci. Rep."},{"key":"1330_CR204","doi-asserted-by":"publisher","first-page":"15178","DOI":"10.1073\/pnas.1416714111","volume":"111","author":"Y Luo","year":"2014","unstructured":"Luo, Y. et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc. Natl Acad. Sci. USA 111, 15178\u201315183 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1330_CR205","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3389\/fcell.2020.00056","volume":"8","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. Interleukin 37 suppresses M1 macrophage polarization through inhibition of the Notch1 and nuclear factor kappa B pathways. Front. Cell Dev. Biol. 8, 56 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1330_CR206","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41392-021-00820-z","volume":"7","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction. Signal Transduct. Target. Ther. 7, 19 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1330_CR207","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.7150\/thno.42416","volume":"10","author":"T Zhao","year":"2020","unstructured":"Zhao, T. et al. IL-37\/ STAT3\/ HIF-1\u03b1 negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Theranostics 10, 4088\u20134100 (2020).","journal-title":"Theranostics"},{"key":"1330_CR208","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01370-0","volume":"20","author":"X Jin","year":"2020","unstructured":"Jin, X., Dai, L., Ma, Y., Wang, J. & Liu, Z. Implications of HIF-1\u03b1 in the tumorigenesis and progression of pancreatic cancer. Cancer Cell Int. 20, 273 (2020).","journal-title":"Cancer Cell Int."},{"key":"1330_CR209","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.2147\/OTT.S201664","volume":"12","author":"P Ouyang","year":"2019","unstructured":"Ouyang, P. et al. IL-37 promotes cell apoptosis in cervical cancer involving Bim upregulation. OncoTargets Ther. 12, 2703\u20132712 (2019).","journal-title":"OncoTargets Ther."},{"key":"1330_CR210","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.celrep.2018.10.087","volume":"25","author":"D Chauhan","year":"2018","unstructured":"Chauhan, D. et al. BAX\/BAK-induced apoptosis results in caspase-8-dependent IL-1b maturation in macrophages. Cell Rep. 25, 2354\u20132368.e2355 (2018).","journal-title":"Cell Rep."},{"key":"1330_CR211","doi-asserted-by":"publisher","first-page":"20167","DOI":"10.1074\/jbc.M115.652321","volume":"290","author":"C Antonopoulos","year":"2015","unstructured":"Antonopoulos, C. et al. Caspase-8 as an effector and regulator of NLRP3 inflammasome signaling. J. Biol. Chem. 290, 20167\u201320184 (2015).","journal-title":"J. Biol. Chem."},{"key":"1330_CR212","first-page":"1227","volume":"61","author":"RN Winter","year":"2001","unstructured":"Winter, R. N., Kramer, A., Borkowski, A. & Kyprianou, N. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res. 61, 1227\u20131232 (2001).","journal-title":"Cancer Res."},{"key":"1330_CR213","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","volume":"97","author":"M Fabbi","year":"2015","unstructured":"Fabbi, M., Carbotti, G. & Ferrini, S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J. Leukoc. Biol. 97, 665\u2013675 (2015).","journal-title":"J. Leukoc. Biol."},{"key":"1330_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155760","volume":"150","author":"Y Zhu","year":"2022","unstructured":"Zhu, Y. et al. Dual role of IL-37 in the progression of tumors. Cytokine 150, 155760 (2022).","journal-title":"Cytokine"},{"key":"1330_CR215","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05755-x","volume":"22","author":"H Ji","year":"2024","unstructured":"Ji, H. et al. IL-18, a therapeutic target for immunotherapy boosting, promotes temozolomide chemoresistance via the PI3K\/AKT pathway in glioma. J. Transl. Med. 22, 951 (2024).","journal-title":"J. Transl. Med."},{"key":"1330_CR216","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/cimb48020202","volume":"48","author":"S Li","year":"2026","unstructured":"Li, S., Gao, C., Zhao, H., Wang, D. & Liu, S. IL-18-mediated tumor immune evasion. Curr. Issues Mol. Biol. 48, 202 (2026).","journal-title":"Curr. Issues Mol. Biol."},{"key":"1330_CR217","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/sj.gt.3300908","volume":"6","author":"T Osaki","year":"1999","unstructured":"Osaki, T. et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther. 6, 808\u2013815 (1999).","journal-title":"Gene Ther."},{"key":"1330_CR218","first-page":"2559","volume":"22","author":"C Liebau","year":"2002","unstructured":"Liebau, C. et al. rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid: a new option as immuno-therapy for osteosarcoma? Anticancer Res. 22, 2559\u20132565 (2002).","journal-title":"Anticancer Res."},{"key":"1330_CR219","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.4049\/jimmunol.160.4.1742","volume":"160","author":"T Osaki","year":"1998","unstructured":"Osaki, T. et al. IFN-gamma-inducing factor\/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160, 1742\u20131749 (1998).","journal-title":"J. Immunol."},{"key":"1330_CR220","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/00002371-199801000-00006","volume":"21","author":"J Tan","year":"1998","unstructured":"Tan, J. et al. Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production. J. Immunother. 21, 48\u201355 (1998).","journal-title":"J. Immunother."},{"key":"1330_CR221","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1172\/JCI1555","volume":"101","author":"CM Coughlin","year":"1998","unstructured":"Coughlin, C. M. et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101, 1441\u20131452 (1998).","journal-title":"J. Clin. Invest."},{"key":"1330_CR222","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/sj.cgt.7700083","volume":"7","author":"I Hara","year":"2000","unstructured":"Hara, I. et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther. 7, 83\u201390 (2000).","journal-title":"Cancer Gene Ther."},{"key":"1330_CR223","first-page":"2541","volume":"90","author":"JP Leonard","year":"1997","unstructured":"Leonard, J. P. et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541\u20132548 (1997). A phase II study of recombinant human IL-12 in patients with advanced cancer that demonstrates excess toxicity and importance of schedule of administration.","journal-title":"Blood"},{"key":"1330_CR224","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1038\/sj.gt.3301827","volume":"9","author":"F Tanaka","year":"2002","unstructured":"Tanaka, F., Hashimoto, W., Robbins, P. D., Lotze, M. T. & Tahara, H. Therapeutic and specific antitumor immunity induced by co-administration of immature dendritic cells and adenoviral vector expressing biologically active IL-18. Gene Ther. 9, 1480\u20131486 (2002).","journal-title":"Gene Ther."},{"key":"1330_CR225","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/sj.gt.3302966","volume":"14","author":"B Xu","year":"2007","unstructured":"Xu, B. et al. Synergistic antileukemia effect of combinational gene therapy using murine beta-defensin 2 and IL-18 in L1210 murine leukemia model. Gene Ther. 14, 1181\u20131187 (2007).","journal-title":"Gene Ther."},{"key":"1330_CR226","first-page":"5853","volume":"62","author":"T Tatsumi","year":"2002","unstructured":"Tatsumi, T., Gambotto, A., Robbins, P. D. & Storkus, W. J. Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res. 62, 5853\u20135858 (2002).","journal-title":"Cancer Res."},{"key":"1330_CR227","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-04-3120","volume":"65","author":"Y Luo","year":"2005","unstructured":"Luo, Y. et al. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence. Cancer Res. 65, 3419\u20133427 (2005).","journal-title":"Cancer Res."},{"key":"1330_CR228","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s002620050345","volume":"43","author":"MJ Micallef","year":"1997","unstructured":"Micallef, M. J. et al. In vivo antitumor effects of murine interferon-gamma-inducing factor\/interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43, 361\u2013367 (1997).","journal-title":"Cancer Immunol. Immunother."},{"key":"1330_CR229","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.4049\/jimmunol.164.6.3330","volume":"164","author":"S Nakamura","year":"2000","unstructured":"Nakamura, S. et al. IFN-gamma-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 164, 3330\u20133336 (2000). Systemic administration of IL-18 and IL-12p70 induced lethal toxicity in mouse models throuh mechanisms not always dependent on IFN\u03b3 release, highlighting findings that warrant reconsideration when desigining multiplexed cytokine armours for adoptive cell transfer.","journal-title":"J. Immunol."},{"key":"1330_CR230","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/00002371-200003000-00002","volume":"23","author":"T Kikuchi","year":"2000","unstructured":"Kikuchi, T. et al. Antitumor activity of interleukin-18 on mouse glioma cells. J. Immunother. 23, 184\u2013189 (2000).","journal-title":"J. Immunother."},{"key":"1330_CR231","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-7-87","volume":"7","author":"CY Chang","year":"2007","unstructured":"Chang, C. Y. et al. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model. BMC Cancer 7, 87 (2007).","journal-title":"BMC Cancer"},{"key":"1330_CR232","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1097\/00002371-200203001-00008","volume":"25","author":"T Iwasaki","year":"2002","unstructured":"Iwasaki, T. et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J. Immunother. 25, S52\u2013S60 (2002).","journal-title":"J. Immunother."},{"key":"1330_CR233","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00262-005-0097-3","volume":"55","author":"Y Nakamura","year":"2006","unstructured":"Nakamura, Y. et al. Effect of interleukin-18 on metastasis of mouse osteosarcoma cells. Cancer Immunol. Immunother. 55, 1151\u20131158 (2006).","journal-title":"Cancer Immunol. Immunother."},{"key":"1330_CR234","doi-asserted-by":"publisher","first-page":"10497","DOI":"10.1158\/0008-5472.CAN-06-1908","volume":"66","author":"UI Chaudhry","year":"2006","unstructured":"Chaudhry, U. I. et al. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res. 66, 10497\u201310504 (2006).","journal-title":"Cancer Res."},{"key":"1330_CR235","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-7-104","volume":"7","author":"I Alagkiozidis","year":"2009","unstructured":"Alagkiozidis, I. et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J. Transl. Med. 7, 104 (2009).","journal-title":"J. Transl. Med."},{"key":"1330_CR236","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000236410","volume":"30","author":"N Yamada","year":"2009","unstructured":"Yamada, N. et al. Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. Tumour Biol. 30, 176\u2013184 (2009).","journal-title":"Tumour Biol."},{"key":"1330_CR237","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003289","volume":"3","author":"RG Carroll","year":"2008","unstructured":"Carroll, R. G. et al. Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS ONE 3, e3289 (2008).","journal-title":"PLoS ONE"},{"key":"1330_CR238","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1538-7445.AM2024-4071","volume":"84","author":"K Martin","year":"2024","unstructured":"Martin, K. et al. The first-in-class PD1-IL18 conjugate BPT567 induces potent anti-tumor immunity by preferentially activating PD1+IL18R+ intratumoral effector T cells in cis. Cancer Res. 84, 4071\u20134071 (2024).","journal-title":"Cancer Res."},{"key":"1330_CR239","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers, J. E. et al. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J. Clin. Invest. 133, e166028 (2023).","journal-title":"J. Clin. Invest."},{"key":"1330_CR240","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1016\/j.celrep.2017.11.063","volume":"21","author":"M Chmielewski","year":"2017","unstructured":"Chmielewski, M. & Abken, H. CAR T cells releasing IL-18 convert to T-bethigh FoxO1low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 21, 3205\u20133219 (2017).","journal-title":"Cell Rep."},{"key":"1330_CR241","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood.2023022293","volume":"144","author":"BD Ng","year":"2024","unstructured":"Ng, B. D. et al. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model. Blood 144, 171\u2013186 (2024).","journal-title":"Blood"},{"key":"1330_CR242","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1096\/fj.201901809R","volume":"34","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells. FASEB J. 34, 1768\u20131782 (2020).","journal-title":"FASEB J."},{"key":"1330_CR243","first-page":"A118","volume":"9","author":"E Breman","year":"2021","unstructured":"Breman, E. et al. Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity. J. Immunother. Cancer 9, A118\u2013A118 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR244","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1016\/j.celrep.2017.09.002","volume":"20","author":"B Hu","year":"2017","unstructured":"Hu, B. et al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. 20, 3025\u20133033 (2017).","journal-title":"Cell Rep."},{"key":"1330_CR245","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1158\/1078-0432.CCR-23-3157","volume":"30","author":"L Fischer-Riepe","year":"2024","unstructured":"Fischer-Riepe, L. et al. Preclinical development of CAR T cells with antigen-inducible IL18 enforcement to treat GD2-positive solid cancers. Clin. Cancer Res. 30, 3564\u20133577 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1330_CR246","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41551-023-01143-w","volume":"8","author":"M Bell","year":"2024","unstructured":"Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK\/STAT signalling. Nat. Biomed. Eng. 8, 380\u2013396 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1330_CR247","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1158\/2159-8290.CD-20-0896","volume":"11","author":"S Lange","year":"2021","unstructured":"Lange, S. et al. A chimeric GM-CSF\/IL18 receptor to sustain CAR T-cell function. Cancer Discov. 11, 1661\u20131671 (2021).","journal-title":"Cancer Discov."},{"key":"1330_CR248","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.ymthe.2024.05.013","volume":"32","author":"CM Hull","year":"2024","unstructured":"Hull, C. M. et al. Granzyme B-activated IL18 potentiates \u03b1\u03b2 and \u03b3\u03b4 CAR T cell immunotherapy in a tumor-dependent manner. Mol. Ther. 32, 2373\u20132392 (2024).","journal-title":"Mol. Ther."},{"key":"1330_CR249","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.omtn.2024.102308","volume":"35","author":"P Justicia-Lirio","year":"2024","unstructured":"Justicia-Lirio, P. et al. First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed\/refractory B cell lymphomas. Mol. Ther. Nucleic Acids 35, 102308 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1330_CR250","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/1097-0142(20011015)92:8<2050::AID-CNCR1544>3.0.CO;2-5","volume":"92","author":"T Kawabata","year":"2001","unstructured":"Kawabata, T. et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92, 2050\u20132055 (2001).","journal-title":"Cancer"},{"key":"1330_CR251","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.3748\/wjg.v13.i32.4345","volume":"13","author":"P Tangkijvanich","year":"2007","unstructured":"Tangkijvanich, P., Thong-Ngam, D., Mahachai, V., Theamboonlers, A. & Poovorawan, Y. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J. Gastroenterol. 13, 4345\u20134349 (2007).","journal-title":"World J. Gastroenterol."},{"key":"1330_CR252","doi-asserted-by":"publisher","first-page":"6137","DOI":"10.1158\/1078-0432.CCR-08-0049","volume":"14","author":"Q Cao","year":"2008","unstructured":"Cao, Q., Cai, W., Niu, G., He, L. & Chen, X. Multimodality imaging of IL-18\u2013binding protein-Fc therapy of experimental lung metastasis. Clin. Cancer Res. 14, 6137\u20136145 (2008).","journal-title":"Clin. Cancer Res."},{"key":"1330_CR253","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/01926230390226681","volume":"31","author":"DJ Herzyk","year":"2003","unstructured":"Herzyk, D. J., Bugelski, P. J., Hart, T. K. & Wier, P. J. Preclinical safety of recombinant human interleukin-18. Toxicol. Pathol. 31, 554\u2013561 (2003).","journal-title":"Toxicol. Pathol."},{"key":"1330_CR254","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/cncr.24100","volume":"115","author":"AA Tarhini","year":"2009","unstructured":"Tarhini, A. A. et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115, 859\u2013868 (2009).","journal-title":"Cancer"},{"key":"1330_CR255","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1158\/2326-6066.CIR-13-0098","volume":"1","author":"F Simpkins","year":"2013","unstructured":"Simpkins, F. et al. Chemoimmunotherapy using pegylated liposomal doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol. Res. 1, 168\u2013178 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"1330_CR256","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/CJI.0b013e31829d7e2e","volume":"36","author":"MJ Robertson","year":"2013","unstructured":"Robertson, M. J. et al. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J. Immunotherapy 36, 331\u2013341 (2013).","journal-title":"J. Immunotherapy"},{"key":"1330_CR257","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/CJI.0000000000000220","volume":"41","author":"MJ Robertson","year":"2018","unstructured":"Robertson, M. J. et al. A dose-escalation study of recombinant human interleukin-18 in combination with ofatumumab after autologous peripheral blood stem cell transplantation for lymphoma. J. Immunother. 41, 151\u2013157 (2018).","journal-title":"J. Immunother."},{"key":"1330_CR258","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1182\/blood-2024-198751","volume":"144","author":"R Banerjee","year":"2024","unstructured":"Banerjee, R. et al. Trial in progress: ST-067 (decoy-resistant IL-18) with teclistamab in multiple myeloma. Blood 144, 7100\u20137100 (2024).","journal-title":"Blood"},{"key":"1330_CR259","doi-asserted-by":"publisher","first-page":"4780","DOI":"10.1182\/blood-2024-204129","volume":"144","author":"E Krakow","year":"2024","unstructured":"Krakow, E. et al. Trials in progress: decoy-resistant interleukin-18 (DR-18) for relapse or pre-emptive treatment of measurable residual disease after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome (DR. DREAM), a phase I trial. Blood 144, 4780\u20134781 (2024).","journal-title":"Blood"},{"key":"1330_CR260","doi-asserted-by":"publisher","first-page":"839783","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke, W. et al. GMP-compliant manufacturing of TRUCKs: CAR T cells targeting GD(2) and releasing inducible IL-18. Front. Immunol. 13, 839783 (2022).","journal-title":"Front. Immunol."},{"key":"1330_CR261","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa2408771","volume":"392","author":"J Svoboda","year":"2025","unstructured":"Svoboda, J. et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N. Engl. J. Med. 392, 1824\u20131835 (2025). The initial demonstration of safety and efficacy of an IL-18-armoured CAR T cell in heavily pretreated patients with relapsed\/refractory lymphoma.","journal-title":"N. Engl. J. Med."},{"key":"1330_CR262","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1182\/blood.2024024104","volume":"144","author":"MJ Frigault","year":"2024","unstructured":"Frigault, M. J. et al. Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies. Blood 144, 1153\u20131167 (2024).","journal-title":"Blood"},{"key":"1330_CR263","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.ymthe.2026.02.039","volume":"34","author":"X Shen","year":"2026","unstructured":"Shen, X., Li, Y. R. & Yang, L. Igniting CAR-NKT cells with IL-18. Mol. Ther. 34, 1882\u20131883 (2026). IL-18 may enhance antitumour function of the natural glycolipid-reactive TCR, and CAR engineered into non-MHC-restricted T cells.","journal-title":"Mol. Ther."},{"key":"1330_CR264","doi-asserted-by":"publisher","first-page":"114771","DOI":"10.1016\/j.jconrel.2026.114771","volume":"393","author":"J Rossowska","year":"2026","unstructured":"Rossowska, J. et al. Extracellular vesicles from IL-18-overexpressing and\/or TGF-\u03b21-deprived tumor cells as an immunogenic antigen source for next-generation DC vaccines. J. Control. Release 393, 114771 (2026).","journal-title":"J. Control. Release"},{"key":"1330_CR265","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61439-0","volume":"16","author":"Z Fan","year":"2025","unstructured":"Fan, Z. et al. Suppression of multiple mouse models of refractory malignancies by reprogramming IL-18 ligand-receptor interaction. Nat. Commun. 16, 6136 (2025).","journal-title":"Nat. Commun."},{"key":"1330_CR266","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011789","volume":"13","author":"TW Bainbridge","year":"2025","unstructured":"Bainbridge, T. W. et al. Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy. J. Immunother. Cancer 13, e011789 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR267","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ymthe.2019.10.007","volume":"28","author":"MA Sellmyer","year":"2020","unstructured":"Sellmyer, M. A. et al. Imaging CAR T cell trafficking with eDHFR as a PET reporter gene. Mol. Ther. 28, 42\u201351 (2020).","journal-title":"Mol. Ther."},{"key":"1330_CR268","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/mi.2015.13","volume":"8","author":"OJ Harrison","year":"2015","unstructured":"Harrison, O. J. et al. Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3+ Treg cell function in the intestine. Mucosal Immunol. 8, 1226\u20131236 (2015).","journal-title":"Mucosal Immunol."},{"key":"1330_CR269","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.mucimm.2023.05.004","volume":"16","author":"F Alvarez","year":"2023","unstructured":"Alvarez, F. et al. IL-18 is required for the TH1-adaptation of TREG cells and the selective suppression of TH17 responses in acute and chronic infections. Mucosal Immunol. 16, 462\u2013475 (2023).","journal-title":"Mucosal Immunol."},{"key":"1330_CR270","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio, M. et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat. Commun. 15, 2542 (2024).","journal-title":"Nat. Commun."},{"key":"1330_CR271","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1182\/blood-2025-276","volume":"146","author":"A Salhotra","year":"2025","unstructured":"Salhotra, A. et al. First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood 146, 276\u2013276 (2025).","journal-title":"Blood"},{"key":"1330_CR272","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003858","volume":"10","author":"N Landolina","year":"2022","unstructured":"Landolina, N. et al. IL-1R8 silencing improves the anti-tumor function of freshly isolated human NK cells. J. Immunother. Cancer 10, e003858 (2022). Blockade of IL-1R8 probably circumvents IL-37-mediated immune suppression and improves NK cell function.","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR273","doi-asserted-by":"publisher","DOI":"10.1002\/eji.70050","volume":"55","author":"D Supino","year":"2025","unstructured":"Supino, D., Garuti, R. & Garlanda, C. Beyond negative regulation: IL-1R8 and IL-1R2 as novel immune checkpoints. Eur. J. Immunol. 55, e70050 (2025).","journal-title":"Eur. J. Immunol."},{"key":"1330_CR274","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009743","volume":"12","author":"E Wickman","year":"2024","unstructured":"Wickman, E. et al. IL-18R supported CAR T cells targeting oncofetal tenascin C for the immunotherapy of pediatric sarcoma and brain tumors. J. Immunother. Cancer 12, e009743 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"1330_CR275","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1038\/onc.2016.444","volume":"36","author":"C Luo","year":"2017","unstructured":"Luo, C. et al. Intracellular IL-37b interacts with Smad3 to suppress multiple signaling pathways and the metastatic phenotype of tumor cells. Oncogene 36, 2889\u20132899 (2017).","journal-title":"Oncogene"},{"key":"1330_CR276","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tips.2006.08.005","volume":"27","author":"AJ Barr","year":"2006","unstructured":"Barr, A. J. & Knapp, S. MAPK-specific tyrosine phosphatases: new targets for drug discovery? Trends Pharmacol. Sci. 27, 525\u2013530 (2006).","journal-title":"Trends Pharmacol. Sci."},{"key":"1330_CR277","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s42003-024-06427-8","volume":"7","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. IL-37d suppresses Rheb-mTORC1 axis independently of TCS2 to alleviate alcoholic liver disease. Commun. Biol. 7, 756 (2024).","journal-title":"Commun. Biol."},{"key":"1330_CR278","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/onc.2017.405","volume":"37","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Intracellular mature IL-37 suppresses tumor metastasis via inhibiting Rac1 activation. Oncogene 37, 1095\u20131106 (2018).","journal-title":"Oncogene"},{"key":"1330_CR279","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/jmcb\/mjw006","volume":"8","author":"J Mora","year":"2016","unstructured":"Mora, J. et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J. Mol. Cell Biol. 8, 426\u2013438 (2016).","journal-title":"J. Mol. Cell Biol."},{"key":"1330_CR280","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4049\/jimmunol.1500648","volume":"198","author":"CS Booker","year":"2017","unstructured":"Booker, C. S. & Grattan, D. R. IL1R9 is evolutionarily related to IL18BP and may function as an IL-18 receptor. J. Immunol. 198, 270\u2013278 (2017).","journal-title":"J. Immunol."},{"key":"1330_CR281","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/1873-3468.14288","volume":"596","author":"S Nimma","year":"2022","unstructured":"Nimma, S. et al. Crystal structure of the Toll\/interleukin-1 receptor (TIR) domain of IL-1R10 provides structural insights into TIR domain signalling. FEBS Lett. 596, 886\u2013897 (2022).","journal-title":"FEBS Lett."},{"key":"1330_CR282","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1684\/ecn.2017.0395","volume":"28","author":"MG Vilia","year":"2017","unstructured":"Vilia, M. G., Tocchetti, M., Fonte, E., Sana, I. & Muzio, M. Characterization of a long isoform of IL-1R8 (TIR8\/SIGIRR). Eur. Cytokine Net. 28, 63\u201369 (2017).","journal-title":"Eur. Cytokine Net."}],"container-title":["Nature Reviews Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01330-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:02:45Z","timestamp":1784217765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41577-026-01330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":282,"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1038\/s41577-026-01330-1","relation":{},"ISSN":["1474-1733","1474-1741"],"issn-type":[{"value":"1474-1733","type":"print"},{"value":"1474-1741","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"16 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}